Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant antibody Fragment F(ab')2 to CD18. Erlizumab, also known as rhuMAb, is a recombinant humanized monoclonal antibody that was an experimental immunosuppressive drug. Erlizumab treat heart attack, stroke, and traumatic shock.
Target
CD18
Type
IgG1
Immunogen
Tissue / cell preparation (Human). (Leucocytes of a patient suffering from a LGL-type leukaemia).
Species Reactivity
Human
Expression Host
E.coli
Applications
Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, ICC and most other immunological methods.
CAS
211323-03-4
Specific Activity
Tested positive against native human antigen.
Protein Construction
Immunoglobulin G1, anti-[human integrin beta2] F[ab"]2 fragment [human-mouse monoclonal γ1-chain], disulfide with human-mouse monoclonal light chain, dimeralpha
Purity
>95.0% as determined by analysis by RP-HPLC.
Size
1mg
Storage
4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided.
BACKGROUND
Antigen Description
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrins alpha-M/beta-2 and alpha-X/beta-2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin alpha-X/beta-2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin alpha-M/beta-2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin alpha-M/beta-2 is also a receptor for factor X. Integrin alpha-D/beta-2 is a receptor for ICAM3 and VCAM1.
Function
binding; glycoprotein binding; protein kinase binding; receptor activity;